Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar:281:133-139.
doi: 10.1016/j.ahj.2024.12.003. Epub 2024 Dec 16.

Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: Rationale and design of the PRO-TAVI trial

Hugo M Aarts  1 , Kimberley I Hemelrijk  2 , Gijs M Broeze  2 , Dirk Jan van Ginkel  3 , Geert A A Versteeg  4 , Daniel C Overduin  3 , Jan G Tijssen  2 , Marcel A M Beijk  2 , Jan Baan  2 , Marije M Vis  2 , Jorrit S Lemkes  2 , Robbert J de Winter  2 , Michael G Dickinson  5 , Adriaan O Kraaijeveld  5 , Mostafa M Mokhles  6 , Thomas C Dessing  6 , Maik J Grundeken  2 , Bimmer E P M Claessen  2 , Pim A L Tonino  7 , Carl E Schotborgh  8 , Martijn Meuwissen  9 , Gert K van Houwelingen  10 , Joanna J Wykrzykowska  11 , Giovanni Amoroso  12 , Tessel N Vossenberg  13 , Pieter A Vriesendorp  14 , Niels van Royen  4 , Jurriën M Ten Berg  15 , Ronak Delewi  16 , Michiel Voskuil  5
Affiliations
Free article

Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: Rationale and design of the PRO-TAVI trial

Hugo M Aarts et al. Am Heart J. 2025 Mar.
Free article

Abstract

Background: Concomitant coronary artery disease (CAD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI). The optimal treatment strategy for CAD is a topic of debate. An initial conservative strategy for CAD in patients undergoing TAVI may be favorable as multiple studies have failed to show an evident beneficial effect of percutaneous coronary intervention (PCI) on mortality after TAVI. However, more randomized, controlled trials are warranted.

Methods: The PeRcutaneous cOronary Intervention before Transcatheter Aortic Valve Implantation (PRO-TAVI) trial is an investigator-initiated, multicenter, open-label, randomized controlled trial comparing TAVI with or without routine preprocedural PCI. A total of 466 patients undergoing TAVI will be randomized in a 1:1 ratio to PCI (reference group) or no PCI (index group). Concomitant CAD is defined as at least 1 stenosis of 70% to 99%, or at least 1 stenosis between 40% and 70% combined with positive physiological measurement in a coronary artery with a minimal diameter of 2.5 mm or bypass graft. The primary endpoint is a composite of all-cause mortality, myocardial infarction, stroke, or type 2 - 4 bleeding at 12 months after randomization, in accordance with Valve Academic Research Consortium-3 criteria. Key secondary endpoints include the individual components of the primary endpoint, revascularization, quality of life and cost-effectiveness. The primary endpoint will be analyzed to assess non-inferiority of deferral of routine PCI in patients undergoing TAVI against the prespecified margin of 11 percentage points.

Conclusion: The PeRcutaneous cOronary intervention before Transcatheter Aortic Valve Implantation (PRO-TAVI) trial is designed to investigate the hypothesis that deferral of routine PCI in patients undergoing TAVI is non-inferior to TAVI with preceding PCI.

Clinical trial registration: clinicaltrials.gov. Unique identifier NCT05078619.

PubMed Disclaimer

Publication types

MeSH terms

Associated data